Barclays
VIGL

Barclays’s Vigil Neuroscience VIGL Stock Holding History

Barclays’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,688
Closed -$22.6K – 5556
2025
Q1 		$22.6K Sell
12,688
-51,361
-80% -$115K ﹤0.01% 4774
2024
Q4 		$109K Buy
64,049
+19,436
+44% +$57.4K ﹤0.01% 4573
2024
Q3 		$152K Sell
44,613
-142
-0.3% -$526 ﹤0.01% 4434
2024
Q2 		$179K Sell
44,755
-68,281
-60% -$234K ﹤0.01% 3631
2024
Q1 		$385K Sell
113,036
-10,759
-9% -$33.6K ﹤0.01% 3751
2023
Q4 		$418K Buy
123,795
+19,205
+18% +$98.8K ﹤0.01% 3993
2023
Q3 		$564K Sell
104,590
-312
-0.3% -$2.15K ﹤0.01% 2720
2023
Q2 		$986K Buy
104,902
+654
+0.6% +$6.18K ﹤0.01% 2318
2023
Q1 		$1.02M Sell
104,248
-1,645
-2% -$18.5K ﹤0.01% 2718
2022
Q4 		$1.32M Buy
105,893
+3,730
+4% +$45.8K ﹤0.01% 2575
2022
Q3 		$929K Buy
102,163
+482
+0.5% +$3.54K ﹤0.01% 2299
2022
Q2 		$262K Sell
101,681
-1,092
-1% -$4.31K ﹤0.01% 3289
2022
Q1 		$722K Buy
+102,773
New +$1.36M ﹤0.01% 2643

Other funds holding VIGL

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

Barclays's VIGL Position: Q2 2025 in Review

Barclays sold out of Vigil Neuroscience (VIGL) in Q2 2025, closing a stake of 12,688 shares — an estimated $22.6K sold.

Barclays first reported a position in VIGL in Q1 2022 and held it in 13 quarters. The position peaked at $1.32M in Q4 2022. 78 funds tracked by Wall St. Rank hold VIGL as of Q2 2025.

  • Barclays reported no remaining Vigil Neuroscience position as of Q2 2025 after selling out during the quarter.
  • Barclays sold 12,688 Vigil Neuroscience shares in Q2 2025, an estimated $22.6K.
  • Barclays first reported a position in Vigil Neuroscience in Q1 2022 and held it in 13 quarters.
  • Barclays's Vigil Neuroscience position peaked at $1.32M in Q4 2022.
  • 78 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q2 2025.

Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.